Ed focuses on Oncology and Infectious Disease, especially in the areas of Medical Affairs and Clinical Development.
He also brings experience in Personalised Medicine, Diagnostics, Digital Health, Ophthalmology, Neuroscience, and Tissue Repair.
A medical doctor by training, Ed has 30 years of industry experience in the UK, Germany and Switzerland. He qualified in medicine in the UK and worked for 7 years in London teaching hospitals, with specialist training in infection. He entered the pharmaceutical industry with Eli Lilly, managing the international multi-indication clinical development program of an oral antibiotic from first patient through regulatory filings into Phase IV, as well as the clinical programs for an injectable antibiotic and an antifungal.
He then moved to Basel (where he remains based), to join F. Hoffmann-La Roche as Medical Director of their global Oncology/Virology business unit, covering the Medical Affairs functions and the evaluation of business development and in-licensing opportunities. Subsequent roles at Roche were as Global Business Leader for MabThera (rituximab) in oncology, Global Business Leader in Ophthalmology, Head of Disease Management, and Program Manager for Integrated Health Care Solutions (Personalised Medicine and Companion Diagnostics).
Ed subsequently had leadership positions in venture-backed medical device companies, as COO of Swiss medtech Kuros Biosurgery, and as Head of Corporate Development at German diagnostics company SIRS-Lab. He has also held pharmaceutical consulting and business development roles at IBM and Infosys, and is an advisor to several start-up companies and organisations.
Ed is deputy head of TranScrip's Oncology team and a member of the Infectious Diseases and Medical Affairs teams.
Within TranScrip he has worked on client projects in Oncology, Infectious Disease, Neuroscience, Immunology, and Diagnostics.